Showing 1 posts of 1 posts found.
Acasti Pharma’s shares plunged by as much as 67% this week as its drug CaPre failed to meet its primary …
Long-acting therapies set to reshape HIV treatment market
MHRA authorises Lynkuet for hot flushes linked to breast cancer therapy
MHRA approves Romvimza for tenosynovial giant cell tumour
NICE recommends allergy immunotherapy tablets for younger children
Dunbar Pharmaceuticals and IPS Pharma announce distribution agreement